Th2-mediated anti-tumour immunity: Friend or foe?

Tissue Antigens

Volumn 70, Issue 1, 2007, Pages 1-11

  Ellyard, J I ^a   Simson, L ^a   Parish, C R ^a  

^a Biology and Environment   (Australia)

Author keywords

Cancer; Eosinophil; Th2 immunity; Tumour immune surveillance

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4;

ADAPTIVE IMMUNITY; ANGIOGENESIS; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL KILLING; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EOSINOPHIL; GRANULOCYTE; HUMAN; IMMUNOSURVEILLANCE; INFLAMMATION; MACROPHAGE ACTIVATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TH2 CELL; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; EOSINOPHILS; HUMANS; IMMUNOLOGIC SURVEILLANCE; MODELS, IMMUNOLOGICAL; NEOPLASMS; TH2 CELLS;

HARNESS;

EID: 34250020832     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2007.00869.x     Document Type: Review

References (99)

1. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004 : 22 : 329 60.
2. Tey SK, Bollard CM, Heslop HE. Adoptive T-cell transfer in cancer immunotherapy. Immunol Cell Biol 2006 : 84 : 281 9.
3. Rammensee HG. Some considerations on the use of peptides and mRNA for therapeutic vaccination against cancer. Immunol Cell Biol 2006 : 84 : 290 4.
4. Parish CR. Cancer immunotherapy: the past, the present and the future. Immunol Cell Biol 2003 : 81 : 106 13.
5. Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 1999 : 5 : 178 86.
6. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000 : 21 : 455 64.
7. Mattes J, Hulett M, Xie W et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 2003 : 197 : 387 93.
8. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998 : 188 : 2357 68.
9. Nishimura T, Iwakabe K, Sekimoto M et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999 : 190 : 617 27.
10. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998 : 187 : 693 702.
11. Corthay A, Skovseth DK, Lundin KU et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005 : 22 : 371 83.
12. Chu Y, Xia M, Lin Y et al. Th2-dominated antitumor immunity induced by DNA immunization with the genes coding for a basal core peptide PDTRP and GM-CSF. Cancer Gene Ther 2006 : 13 : 510 9.
13. Mautner J, Jaffee EM, Pardoll DM. Tumor-specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigens. Int J Cancer 2005 : 115 : 752 9.
14. Tanaka Y, Kobayashi K, Takahashi A et al. Inhibition of inflammatory liver injury by a monoclonal antibody against lymphocyte function-associated antigen-1. J Immunol 1993 : 151 : 5088 95.
15. Modesti A, Masuelli L, Modica A et al. Ultrastructural evidence of the mechanisms responsible for interleukin-4-activated rejection of a spontaneous murine adenocarcinoma. Int J Cancer 1993 : 53 : 988 93.
16. Musiani P, Allione A, Modica A et al. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. Lab Invest 1996 : 74 : 146 57.
17. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 1992 : 257 : 548 51.
18. Pericle F, Giovarelli M, Colombo MP et al. An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J Immunol 1994 : 153 : 5659 73.
19. Bosco M, Giovarelli M, Forni M et al. Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J Immunol 1990 : 145 : 3136 43.
20. Paul WE. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 1991 : 77 : 1859 70.
21. Noffz G, Qin Z, Kopf M, Blankenstein T. Neutrophils but not eosinophils are involved in growth suppression of IL-4-secreting tumors. J Immunol 1998 : 160 : 345 50.
22. Samoszuk M, Deng T, Hamamura MJ, Su MY, Asbrock N, Nalcioglu O. Increased blood clotting, microvascular density, and inflammation in eotaxin-secreting tumors implanted into mice. Am J Pathol 2004 : 165 : 449 56.
23. Volpert OV, Fong T, Koch AE et al. Inhibition of angiogenesis by interleukin 4. J Exp Med 1998 : 188 : 1039 46.
24. Saleh M, Davis ID, Wilks AF. The paracrine role of tumour-derived mIL-4 on tumour-associated endothelium. Int J Cancer 1997 : 72 : 664 72.
25. Schuler T, Kornig S, Blankenstein T. Tumor rejection by modulation of tumor stromal fibroblasts. J Exp Med 2003 : 198 : 1487 93.
26. Conticello C, Pedini F, Zeuner A et al. IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol 2004 : 172 : 5467 77.
27. Falkensammer C, Johrer K, Gander H et al. IL-4 inhibits the TNF-alpha induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-alpha to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses. Cancer Immunol Immunother 2006 : 55 : 1228 37.
28. Whitehead RP, Unger JM, Goodwin JW et al. Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a Southwest Oncology Group study. J Immunother 1998 : 21 : 440 6.
29. Whitehead RP, Lew D, Flanigan RC et al. Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a southwest oncology group study. J Immunother 2002 : 25 : 352 8.
30. Margolin K, Aronson FR, Sznol M et al. Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J Immunother Emphasis Tumor Immunol 1994 : 15 : 147 53.
31. Sosman JA, Bartemes K, Offord KP et al. Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. Clin Cancer Res 1995 : 1 : 805 12.
32. Fallon PG, Jolin HE, Smith P et al. IL-4 induces characteristic Th2 responses even in the combined absence of IL-5, IL-9, and IL-13. Immunity 2002 : 17 : 7 17.
33. Zurawski G, de Vries JE. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 1994 : 15 : 19 26.
34. Terabe M, Park JM, Berzofsky JA. Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother 2004 : 53 : 79 85.
35. Lebel-Binay S, Laguerre B, Quintin-Colonna F et al. Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13. Eur J Immunol 1995 : 25 : 2340 8.
36. Ma HL, Whitters MJ, Jacobson BA, Donaldson DD, Collins M, Dunussi-Joannopoulos K. Tumor cells secreting IL-13 but not IL-13Ralpha2 fusion protein have reduced tumorigenicity in vivo. Int Immunol 2004 : 16 : 1009 17.
37. Singer M, Lefort J, Vargaftig BB. Granulocyte depletion and dexamethasone differentially modulate airways hyperreactivity, inflammation, mucus accumulation, and secretion induced by rmIL-13 or antigen. Am J Respir Cell Mol Biol 2002 : 26 : 74 84.
38. Terabe M, Matsui S, Noben-Trauth N et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000 : 1 : 515 20.
39. Caput D, Laurent P, Kaghad M et al. Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain. J Biol Chem 1996 : 271 : 16921 6.
40. Zhang JG, Hilton DJ, Willson TA et al. Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein. Evidence that it is distinct from the cloned Il-13 receptor and Il-4 receptor alpha-chains. J Biol Chem 1997 : 272 : 9474 80.
41. Park JM, Terabe M, van den Broeke LT, Donaldson DD, Berzofsky JA. Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13. Int J Cancer 2005 : 114 : 80 7.
42. Skinnider BF, Kapp U, Mak TW. The role of interleukin 13 in classical Hodgkin lymphoma. Leuk Lymphoma 2002 : 43 : 1203 10.
43. Kawakami K, Kawakami M, Snoy PJ, Husain SR, Puri RK. In vivo overexpression of IL-13 receptor alpha2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J Exp Med 2001 : 194 : 1743 54.
44. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 2005 : 78 : 1043 51.
45. Wynn TA, Morawetz R, Scharton-Kersten T et al. Analysis of granuloma formation in double cytokine-deficient mice reveals a central role for IL-10 in polarizing both T helper cell 1- and T helper cell 2-type cytokine responses in vivo. J Immunol 1997 : 159 : 5014 23.
46. Anderson CF, Oukka M, Kuchroo VJ, Sacks D. CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med 2007 : 204 : 285 97.
47. Jankovic D, Kullberg MC, Feng CG et al. Conventional T-bet(+)Foxp3(-) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J Exp Med 2007 : 204 : 273 83.
48. Matsuda M, Salazar F, Petersson M et al. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 1994 : 180 : 2371 6.
49. Hagenbaugh A, Sharma S, Dubinett SM et al. Altered immune responses in interleukin 10 transgenic mice. J Exp Med 1997 : 185 : 2101 10.
50. Sharma S, Stolina M, Lin Y et al. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 1999 : 163 : 5020 8.
51. Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 2007 : 18 : 171 82.
52. Dummer W, Bastian BC, Ernst N, Schanzle C, Schwaaf A, Brocker EB. Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int J Cancer 1996 : 66 : 607 10.
53. Petersson M, Charo J, Salazar-Onfray F et al. Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J Immunol 1998 : 161 : 2099 105.
54. Salazar-Onfray F, Petersson M, Franksson L et al. IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression. J Immunol 1995 : 154 : 6291 8.
55. Stearns ME, Rhim J, Wang M. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res 1999 : 5 : 189 96.
56. Ishibashi S, Ohashi Y, Suzuki T et al. Tumor-associated tissue eosinophilia in human esophageal squamous cell carcinoma. Anticancer Res 2006 : 26 : 1419 24.
57. Iwasaki K, Torisu M, Fujimura T. Malignant tumor and eosinophils. I. Prognostic significance in gastric cancer. Cancer 1986 : 58 : 1321 7.
58. Goldsmith MM, Belchis DA, Cresson DH, Merritt WD III., Askin FB. The importance of the eosinophil in head and neck cancer. Otolaryngol Head Neck Surg 1992 : 106 : 27 33.
59. Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brunner N, Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999 : 189 : 487 95.
60. Fernandez-Acenero MJ, Galindo-Gallego M, Sanz J, Aljama A. Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer 2000 : 88 : 1544 8.
61. Pretlow TP, Keith EF, Cryar AK et al. Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res 1983 : 43 : 2997 3000.
62. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989 : 57 : 503 12.
63. Simson L, Ellyard J, Dent L et al. Regulation of carcinogenesis by interleukin-5 and CCL11: a potential role for eosinophils in tumour immune surveillance. J Immunol 2007 : 178 : 4222 9.
64. Furbert-Harris PM, Laniyan I, Harris D et al. Activated eosinophils infiltrate MCF-7 breast multicellular tumor spheroids. Anticancer Res 2003 : 23 : 71 8.
65. Furbert-Harris P, Parish-Gause D, Laniyan I et al. Inhibition of prostate cancer cell growth by activated eosinophils. Prostate 2003 : 57 : 165 75.
66. Gleich GJ, Adolphson CR. The eosinophilic leukocyte: structure and function. Adv Immunol 1986 : 39 : 177 253.
67. Nutten S, Papin JP, Woerly G et al. Selectin and Lewis(x) are required as co-receptors in antibody-dependent cell-mediated cytotoxicity of human eosinophils to Schistosoma mansoni schistosomula. Eur J Immunol 1999 : 29 : 799 808.
68. Puxeddu I, Ribatti D, Crivellato E, Levi-Schaffer F. Mast cells and eosinophils: a novel link between inflammation and angiogenesis in allergic diseases. J Allergy Clin Immunol 2005 : 116 : 531 6.
69. Hoshino M, Nakamura Y, Hamid QA. Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. J Allergy Clin Immunol 2001 : 107 : 1034 8.
70. Puxeddu I, Alian A, Piliponsky AM, Ribatti D, Panet A, Levi-Schaffer F. Human peripheral blood eosinophils induce angiogenesis. Int J Biochem Cell Biol 2005 : 37 : 628 36.
71. Tataroglu C, Kargi A, Ozkal S, Esrefoglu N, Akkoclu A. Association of macrophages, mast cells and eosinophil leukocytes with angiogenesis and tumor stage in non-small cell lung carcinomas (NSCLC). Lung Cancer 2004 : 43 : 47 54.
72. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003 : 3 : 23 35.
73. Anthony RM, Urban JF Jr., Alem F et al. Memory T(H)2 cells induce alternatively activated macrophages to mediate protection against nematode parasites. Nat Med 2006 : 12 : 955 60.
74. Zimmermann N, King NE, Laporte J et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest 2003 : 111 : 1863 74.
75. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006 : 66 : 605 12.
76. Rodriguez PC, Quiceno DG, Zabaleta J et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004 : 64 : 5839 49.
77. Currie GA, Gyure L, Cifuentes L. Microenvironmental arginine depletion by macrophages in vivo. Br J Cancer 1979 : 39 : 613 20.
78. Yeatman TJ, Risley GL, Brunson ME. Depletion of dietary arginine inhibits growth of metastatic tumor. Arch Surg 1991 : 126 : 1376 81 discussion 1381-2.
79. Higuchi M, Higashi N, Taki H, Osawa T. Cytolytic mechanisms of activated macrophages. Tumor necrosis factor and L-arginine-dependent mechanisms act synergistically as the major cytolytic mechanisms of activated macrophages. J Immunol 1990 : 144 : 1425 31.
80. Feun L, Savaraj N. Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin Investig Drugs 2006 : 15 : 815 22.
81. Ramalingam TR, Reiman RM, Wynn TA. Exploiting worm and allergy models to understand Th2 cytokine biology. Curr Opin Allergy Clin Immunol 2005 : 5 : 392 8.
82. Sad S, Marcotte R, Mosmann TR. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity 1995 : 2 : 271 9.
83. Noble A, Macary PA, Kemeny DM. IFN-gamma and IL-4 regulate the growth and differentiation of CD8+ T cells into subpopulations with distinct cytokine profiles. J Immunol 1995 : 155 : 2928 37.
84. Dobrzanski MJ, Reome JB, Dutton RW. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases. J Immunol 1999 : 162 : 6671 80.
85. Helmich BK, Dutton RW. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors. J Immunol 2001 : 166 : 6500 8.
86. Musiani P, Modesti A, Giovarelli M et al. Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol Today 1997 : 18 : 32 6.
87. Rodolfo M, Zilocchi C, Accornero P, Cappetti B, Arioli I, Colombo MP. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer. J Immunol 1999 : 163 : 1923 8.
88. Kemp RA, Ronchese F. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J Immunol 2001 : 167 : 6497 502.
89. Olver S, Groves P, Buttigieg K et al. Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells. Cancer Res 2006 : 66 : 571 80.
90. Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007 : 19 : 209 16.
91. Barbera-Guillem E, Nelson MB, Barr B et al. B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol Immunother 2000 : 48 : 541 9.
92. Shah S, Divekar AA, Hilchey SP et al. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer 2005 : 117 : 574 86.
93. Perricone MA, Smith KA, Claussen KA et al. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother 2004 : 27 : 273 81.
94. Riedel F, Zaiss I, Herzog D, Gotte K, Naim R, Hormann K. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Res 2005 : 25 : 2761 5.
95. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006 : 80 : 227 36.
96. Rowley DA, Stach RM. B lymphocytes secreting IgG linked to latent transforming growth factor-beta prevent primary cytolytic T lymphocyte responses. Int Immunol 1998 : 10 : 355 63.
97. Barbera-Guillem E, May KF Jr., Nyhus JK, Nelson MB. Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies. Neoplasia 1999 : 1 : 453 60.
98. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005 : 7 : 411 23.
99. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006 : 6 : 715 27.